Elevated levels of TGF-β can inhibit anti-tumour immunity by activating SMADs and NFAT to induce the expression of FOXP3 in CD4+ T cells, which can promote their differentiation to a Treg phenotype (130). Here, FOXP3 is linked to neoplasm.